Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Dot Blot, ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 3C11

Concentration

1 mg/ml

View all alpha-Synuclein Antibodies »

Product Specifications

Immunogen

Human alpha-Synuclein monomer

Localization

Cytoplasm|Cytosol|Membrane|Nucleus|Cell Junction|Synapse

Specificity

Binds within the 81-130 aa region of human ASYN, determined using WB and ELISA with corresponding peptides. Detects ~14 kDa band corresponding to ASYN. Band at ~30 kDa is a dimer.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for alpha-Synuclein Antibody (3C11)

Western Blot: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Western Blot: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Western Blot: alpha-Synuclein Antibody (3C11) [NBP3-18258] - Western Blot analysis of Human Brain showing detection of 14 kDa alpha-Synuclein protein using Mouse Anti-alpha-Synuclein Monoclonal Antibody, Clone 3C11 (NBP3-18258). Lane 1: Molecular Weight Ladder (MW). Lane 2: Parkinson brain cell lystate. Lane 3: Human brain cell lysate. Load: 15 ug. Block: 5% Skim Milk in 1X TBST. Primary Antibody: Mouse Anti-alpha-Synuclein Monoclonal Antibody (NBP3-18258) at 1:1000 for 2 hours at RT. Secondary Antibody: Goat Anti-Mouse HRP:IgG at 1:3000 for 1 hour at RT. Color Development: ECL solution (Super Signal West Pico) for 5 min in RT. Predicted/Observed Size: 14 kDa. Other Band(s): 100 kDa (oligomer).
Immunocytochemistry/ Immunofluorescence: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Immunocytochemistry/ Immunofluorescence: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Immunocytochemistry/Immunofluorescence: alpha-Synuclein Antibody (3C11) [NBP3-18258] - Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-alpha-Synuclein Monoclonal Antibody, Clone 3C11 (NBP3-18258). Tissue: Neuroblastoma cell line (SK-N-BE). Species: Human. Fixation: 4% Formaldehyde for 15 min at RT. Primary Antibody: Mouse Anti-alpha-Synuclein Monoclonal Antibody (NBP3-18258) at 1:100 for 60 min at RT. Secondary Antibody: Goat Anti-Mouse ATTO 488 at 1:200 for 60 min at RT. Counterstain: Phalloidin Texas Red F-Actin stain; DAPI (blue) nuclear stain at 1:1000, 1:5000 for 60 min at RT, 5 min at RT. Localization: Cytoplasm: weak; Nucleus: Med. Magnification: 60X. (A) DAPI (blue) nuclear stain. (B) Phalloidin Texas Red F-Actin stain. (C) alpha-Synuclein Antibody. (D) Composite.
Immunohistochemistry: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Immunohistochemistry: alpha-Synuclein Antibody (3C11) [NBP3-18258]

Immunohistochemistry: alpha-Synuclein Antibody (3C11) [NBP3-18258] - Immunohistochemistry analysis using Mouse Anti-alpha-Synuclein Monoclonal Antibody, Clone 3C11 (NBP3-18258). Tissue: cerebellum. Species: Rat. Fixation: Formalin fixed, paraffin embedded. Primary Antibody: Mouse Anti-alpha-Synuclein Monoclonal Antibody (NBP3-18258) at 1:25 for 1 hour at RT. Secondary Antibody: Goat Anti-Mouse IgG: Alexa Fluor 488. Counterstain: Actin-binding Phalloidin-Alexa Fluor 633; DAPI (blue) nuclear stain. Magnification: 63X. (A) DAPI (blue) nuclear stain. (B) Phalloidin Alex Fluor 633 F-Actin stain. (C) alpha-Synuclein Antibody (D) Composite.
View 1 more images

Applications for alpha-Synuclein Antibody (3C11)

Application
Recommended Usage

Dot Blot

1:1000

ELISA

1:1000

Immunocytochemistry/ Immunofluorescence

1:100

Western Blot

1:1000
Application Notes
Optimal dilutions for assays should be determined by the user.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS pH 7.4, 50% glycerol

Preservative

0.09% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: alpha-Synuclein

Alpha-synuclein, a member of the synuclein family, is a protein that was first identified in 1988 whose name is derived from its localization to both the synapse and nucleus (1-3). Specifically, it is expressed primarily in the brain, including Lewy Bodies (1-6). Alpha-synuclein is encoded by the SNCA gene, located on chromosome 4p21, and is processed as a 140 amino acid (aa) protein with a theoretical molecular weight of 14 kDa (1,2,4). Structurally alpha-synuclein consists of a N-terminal binding domain (1-60 aa), a central domain core region called the non-amyloid-beta component (NAC) (61-95 aa), and a C-terminal domain (96-140 aa) (1-3). The N-terminal region contains aa repeats with a KTKEGV consensus sequence that gives the protein its alpha-helical structure that associates with lipid membranes (1-4). The hydrophobic NAC region is responsible for alpha-synuclein aggregation and fibril formation (1-4). The acidic C-terminal tail is largely unstructured but can be targeted for post-translational modifications (1-4). The function of alpha-synuclein is not entirely understood, but it is shown to have a role in suppression of apoptosis, acting as a molecular chaperone, regulating glucose, and modulating calmodulin activity (1,3).

A number of studies have revealed that alpha-synuclein aggregation is a hallmark feature in a number of neurodegenerative diseases, referred to as synucleinopathies (2-4). Alpha-synuclein protein aggregates are a large component of Lewy bodies that are present in Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (1-6). Research has shown phosphorylation of alpha-synuclein at Ser129 moves the protein from the nucleus to the cytoplasm and promotes fibril formation associated with synucleinopathies (1,2,5). Recent studies also suggest that alpha-synuclein accumulation can prevent mitochondrial import machinery causing mitochondrial dysfunction that is often observed in neurodegeneration (5). It is thought that preventing alpha-synuclein aggregation may prevent PD, thus alpha-synuclein is a target for many potential therapeutic interventions aimed at decreasing aggregate formation or increasing clearance (1,2,4-6).

References

1. Villar-Pique, A., Lopes da Fonseca, T., & Outeiro, T. F. (2016). Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. Journal of neurochemistry. https://doi.org/10.1111/jnc.13249

2. Emamzadeh F. N. (2016). Alpha-synuclein structure, functions, and interactions. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. https://doi.org/10.4103/1735-1995.181989

3. Burre J. (2015). The Synaptic Function of alpha-Synuclein. Journal of Parkinson's disease. https://doi.org/10.3233/JPD-150642

4. Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature reviews. Neuroscience. https://doi.org/10.1038/nrn3406

5. Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018). Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2017.04.004

6. O'Leary, E. I., & Lee, J. C. (2019). Interplay between alpha-synuclein amyloid formation and membrane structure. Biochimica et biophysica acta. Proteins and proteomics. https://doi.org/10.1016/j.bbapap.2018.09.012

Alternate Names

NACP, PARK1, PARK4, SNCA, Synuclein-alpha

Gene Symbol

SNCA

Additional alpha-Synuclein Products

Product Documents for alpha-Synuclein Antibody (3C11)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for alpha-Synuclein Antibody (3C11)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.